Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV-Reference-Cited by-同舟云学术

Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV

Published:2013-10 Issue:10 Volume:8 Page:1021-1034
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

O’Halloran Jane A¹,Satchell Claudette S²,Mallon Patrick WG³⁴

Affiliation:

1. HIV Molecular Research Group, University College Dublin School of Medicine and Medical Science, Catherine McAuley Education & Research Centre, Nelson Street, Dublin 7, Ireland.

2. Justice Health Research Program, Kirby Institute, University of New South Wales, Sydney, NSW, Australia

3. HIV Molecular Research Group, University College Dublin School of Medicine and Medical Science, Catherine McAuley Education & Research Centre, Nelson Street, Dublin 7, Ireland

4. Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland

Abstract

As a result of major advances in the management of HIV over the last two decades, patients living with HIV are now encountering comorbidities commonly associated with aging. Cardiovascular disease is the leading cause of death worldwide. As the population living with HIV ages, understanding cardiovascular disease in the setting of HIV is of increasing importance. This review examines the complex interplay between cardiovascular disease, HIV infection and the drugs used to treat it, with particular emphasis on the contribution of dyslipidemia.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl.13.87

Reference116 articles.

1. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population

2. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals

3. RodgerA, Lodwick R, Schechter Met al.Mortality in patients with well-controlled HIV and high CD4 counts in the cART arms of the SMART and ESPRIT randomized clinical trials compared to the general population. Presented at:19th Conference on Retroviruses and Opportunistic Infections (CROI 2012). WA, USA, 5–8 March 2012 (Abstract 638).

4. CDC. HIV/AIDS Surveillance Report, 2005. US Department of Health and Human Services, Centres for Disease Control and Prevention, GA, USA,17,1–54 (2007).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Étude interventionnelle sur le Dolutégravir et les autres antirétroviraux dans l´athérosclérosclérose infra-clinique en milieu hospitalier de Kinshasa;Pan African Medical Journal;2023

2. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV;JAIDS Journal of Acquired Immune Deficiency Syndromes;2020-08-01

3. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen;AIDS;2019-08-01

4. Underutilization of Statins When Indicated in HIV-Seropositive and Seronegative Women;AIDS Patient Care and STDs;2017-11

5. Low HDL-cholesterol among HIV-1 infected and HIV-1 uninfected individuals in Nairobi, Kenya;Lipids in Health and Disease;2017-06-09